Format

Send to

Choose Destination
Ann Biol Clin (Paris). 2016 Jun 1;74(3):259-67. doi: 10.1684/abc.2016.1158.

Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia.

Author information

1
Inserm UMR-S 1139, Physiopathologie et pharmacotoxicologie placentaire humaine, Paris, France, Département de gynécologie obstétrique I, Maternité Port-Royal, Centre hospitalier universitaire Cochin-Broca-Hôtel-Dieu, Groupe Hospitalier Universitaire Ouest, AP-HP, Paris, France, Fondation Premup, Paris, France, DHU Risques et grossesse, Paris, France, PRES Sorbonne Paris-Cité, Université Paris-Descartes, Paris, France.
2
Inserm UMR-S 1139, Physiopathologie et pharmacotoxicologie placentaire humaine, Paris, France, Département de gynécologie obstétrique, CHI Créteil, CRC CHI Créteil, Université Paris Est Créteil, France.
3
Inserm UMR-S 1139, Physiopathologie et pharmacotoxicologie placentaire humaine, Paris, France, Fondation Premup, Paris, France, Département de gynécologie obstétrique, CHI Créteil, CRC CHI Créteil, Université Paris Est Créteil, France.
4
Inserm UMR-S 1139, Physiopathologie et pharmacotoxicologie placentaire humaine, Paris, France, Fondation Premup, Paris, France, DHU Risques et grossesse, Paris, France, PRES Sorbonne Paris-Cité, Université Paris-Descartes, Paris, France.
5
Laboratoire d'hormonologie, Centre hospitalier universitaire Cochin Broca-Hôtel-Dieu, Groupe hospitalier universitaire Ouest, AP-HP, Paris, France.
6
Inserm UMR-S 1139, Physiopathologie et pharmacotoxicologie placentaire humaine, Paris, France, Fondation Premup, Paris, France, DHU Risques et grossesse, Paris, France, PRES Sorbonne Paris-Cité, Université Paris-Descartes, Paris, France, Laboratoire d'hormonologie, Centre hospitalier universitaire Cochin Broca-Hôtel-Dieu, Groupe hospitalier universitaire Ouest, AP-HP, Paris, France.

Abstract

The placental growth factor (PlGF) and its soluble receptor (sFlt-1) are circulating angiogenic factors. During pregnancy these factors are released by the placenta into the maternal circulation. Preeclampsia affects 2-7% of pregnant women according to their risk factors and is characterized by high blood pressure and the onset of de novo proteinuria in the second half of pregnancy. Alterations of the sFlt-1/PlGF ratio in preeclampsia correlate with the diagnosis and adverse outcomes, particularly when the disease presents prematurely (<34 weeks). These factors can be assayed in maternal blood and measuring the sFlt-1/PlGF ratio is now available. We propose in this work to update the knowledge of these two molecules, describe their roles and evolution during normal pregnancy and preeclampsia, and finally to focus on the available assays.

KEYWORDS:

angiogenic factors; placenta; placental growth factor; prééclampsia; sFlt-1

PMID:
27237799
DOI:
10.1684/abc.2016.1158
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for John Libbey Eurotext
Loading ...
Support Center